Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

M Frosco1, L E Lawrence, J F Barrett

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA.

Expert Opinion on Investigational Drugs
|July 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal outcomes at 3 months after planned caesarean section versus planned vaginal birth for twin pregnancies in the Twin Birth Study: a randomised controlled trial.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Bacterial resistance.

IDrugs : the investigational drugs journal·2005
Same author

Quinolone update.

IDrugs : the investigational drugs journal·2005
Same author

Targets, targets everywhere--so where are the new antibacterial drugs?

IDrugs : the investigational drugs journal·2005
Same author

American Society of Microbiology - 100th General Meeting.

IDrugs : the investigational drugs journal·2005
Same author

Antifungal agents and efflux pump inhibitors.

IDrugs : the investigational drugs journal·2005
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Researchers are addressing the growing antimicrobial resistance crisis by exploring new drug targets and modifying existing antimicrobials. This focus highlights efforts to combat resistant bacteria and fungi effectively.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • The International Congress of Antimicrobial Agents and Chemotherapy (ICAAC) meeting convened over 10,000 scientists.
  • A significant concern discussed was the escalating resistance rates in bacteria and fungi.
  • Understanding the mechanisms driving this antimicrobial resistance is crucial.

Purpose of the Study:

  • To highlight key research trends presented at the ICAAC meeting.
  • To focus on the challenges posed by antimicrobial resistance.
  • To outline strategies for combating the emerging resistance crisis.

Main Methods:

  • Presentations focused on the mechanisms of antimicrobial resistance.
  • Research explored modifications to existing antimicrobial drugs.

Related Experiment Videos

  • Novel antimicrobial classes and potential new drug targets were discussed.

    • Main Results:

    • The meeting underscored the increasing prevalence of antimicrobial resistance.
    • Various approaches to combat resistance were presented.
    • New therapeutic strategies are under development.

    Conclusions:

    • Combating antimicrobial resistance requires continuous innovation in drug development.
    • Exploring novel targets and modifying existing antimicrobials are key strategies.
    • The scientific community is actively engaged in addressing this global health threat.